{
    "root": "0d1de286-f5ba-4b7c-b161-8fcb8aac8b14",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "NEUPOGEN",
    "value": "20250418",
    "ingredients": [
        {
            "name": "FILGRASTIM",
            "code": "PVI5M0M1GW"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "neupogen leukocyte growth factor indicated decrease incidence infection‚ manifested febrile neutropenia‚ patients nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated significant incidence severe neutropenia fever ( 1.1 ) reduce time neutrophil recovery duration fever , following induction consolidation chemotherapy treatment patients acute myeloid leukemia ( aml ) ( 1.2 ) reduce duration neutropenia neutropenia-related sequelae‚ e.g.‚ febrile neutropenia , patients nonmyeloid malignancies undergoing myeloablative chemotherapy followed bone marrow transplantation ( bmt ) ( 1.3 ) mobilize autologous hematopoietic progenitor cells peripheral blood collection leukapheresis ( 1.4 ) reduce incidence duration sequelae severe neutropenia ( e.g.‚ fever‚ infections‚ oropharyngeal ulcers ) symptomatic patients congenital neutropenia‚ cyclic neutropenia‚ idiopathic neutropenia ( 1.5 ) increase survival patients acutely exposed myelosuppressive doses radiation ( hematopoietic syndrome acute radiation syndrome ) ( 1.6 )",
    "contraindications": "patients cancer receiving myelosuppressive chemotherapy induction and/or consolidation chemotherapy aml recommended starting dose 5 mcg/kg/day subcutaneous injection , short intravenous infusion ( 15 30 minutes ) , continuous intravenous infusion . full prescribing information recommended adjustments timing ( 2.1 ) patients cancer undergoing bone marrow transplantation 10 mcg/kg/day given intravenous infusion longer 24 hours . full prescribing information recommended adjustments timing ( 2.2 ) patients undergoing autologous peripheral blood progenitor cell collection therapy 10 mcg/kg/day subcutaneous injection ( 2.3 ) administer least 4 days first leukapheresis procedure continue last leukapheresis ( 2.3 ) patients congenital neutropenia recommended starting dose 6 mcg/kg subcutaneous injection twice daily ( 2.4 ) patients cyclic idiopathic neutropenia recommended starting dose 5 mcg/kg subcutaneous injection daily ( 2.4 ) patients acutely exposed myelosuppressive doses radiation 10 mcg/kg/day subcutaneous injection ( 2.5 )",
    "warningsAndPrecautions": "neupogen injection clear , colorless , preservative-free solution supplied :",
    "adverseReactions": "neupogen contraindicated patients history serious allergic human granulocyte colony-stimulating factors filgrastim pegfilgrastim [ ( 5.3 ) ] .",
    "indications_original": "NEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 )",
    "contraindications_original": "Patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML Recommended starting dose is 5 mcg/kg/day subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion.  See Full Prescribing Information for recommended dosage adjustments and timing of administration ( 2.1 ) Patients with cancer undergoing bone marrow transplantation 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours.  See Full Prescribing Information for recommended dosage adjustments and timing of administration ( 2.2 ) Patients undergoing autologous peripheral blood progenitor cell collection and therapy 10 mcg/kg/day subcutaneous injection ( 2.3 ) Administer for at least 4 days before first leukapheresis procedure and continue until last leukapheresis ( 2.3 ) Patients with congenital neutropenia Recommended starting dose is 6 mcg/kg subcutaneous injection twice daily ( 2.4 ) Patients with cyclic or idiopathic neutropenia Recommended starting dose is 5 mcg/kg subcutaneous injection daily ( 2.4 ) Patients acutely exposed to myelosuppressive doses of radiation 10 mcg/kg/day subcutaneous injection ( 2.5 )",
    "warningsAndPrecautions_original": "NEUPOGEN injection is a clear, colorless, preservative-free solution supplied as:",
    "adverseReactions_original": "NEUPOGEN is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim [see Warnings and Precautions (5.3)]."
}